WebPharmacodynamic properties for further information). Long-term antibody persistence data following vaccination with NIMENRIX are available up to 10 years after vaccination (see … WebPfizer develops Safety Data Sheets (SDSs) for our products for the benefit of our customers who are employers. We prepare, maintain, and provide the SDSs pursuant to applicable …

WHO PRODUCT INFORMATION

Web22 Jun 2015 · Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. Web2. What you need to know before you receive Nimenrix 3. How Nimenrix is given 4. Possible side effects 5. How to store Nimenrix 6. Contents of the pack and other information . 1. What Nimenrix is and what it is used for . What Nimenrix is and what it is used for . Nimenrix is a vaccine which helps protect against infections caused by bacteria ... filetage whitworth gaz

Nimenrix Drug / Medicine Information - News-Medical.net

Web5 Apr 2024 · The Australian Technical Advisory Group on Immunisation (ATAGI) has developed advice on the introduction of meningococcal ACWY vaccine (Nimenrix®) for adolescents through the National Immunisation Program (NIP). It includes information about: recommendations for the use of meningococcal ACWY vaccine WebTrade Name Information Sheet Active Ingredient(s) Nimenrix: CMI PI: Tetanus toxoid; Meningococcal polysaccharide - Group Y; Meningococcal polysaccharide - Group C; Meningococcal polysaccharide - Group A; Meningococcal polysaccharide - Group W135 WebNIMENRIX is indicated for active immunisation of individuals from 6 weeks of age against invasive meningococcal diseases caused by . Neisseria meningitidis. groups A, C, W-135 … filetage whitworth